Scientific and Clinical Validation
- First-ever selective FABP5 inhibitor to enter clinical trials, currently in Phase 1
- Lead development candidate in Artelo’s Fatty Acid Binding Protein (FABP) Inhibitor platform with high potency and selectivity (learn more about FABPs)
- FABPs are intracellular proteins that chaperone lipids including endocannabinoids and fatty acids
- In vivo efficacy in models of pain, anxiety, and inflammation through mechanisms involving the endocannabinoid system
- In vivo efficacy in animal models of prostate cancer through mechanisms involving the regulation of pro-tumoral and pro-metastatic proteins
- FABP5 inhibition may have therapeutic value in Chemotherapy-Induced Peripheral Neuropathy (CIPN), other painful neuropathies, and dermatology
- FABP5 is a validated target in breast, prostate and cervical cancers, and is implicated in many other cancer types
Learn more about ART26.12